Non-steroid anti-inflammatory drugs, prostaglandins, and cancer

Cell and Bioscience

Volumn 3, Issue 1, 2013, Pages

  Allaj, Viola ^a   Guo, Changxiong ^a   Nie, Daotai ^a  

^a SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84874853682     PISSN: None     EISSN: 20453701     Source Type: Journal    
DOI: 10.1186/2045-3701-3-8     Document Type: Review

References (152)

1. Fürstenberger G, Krieg P, Müller-Decker K, Habenicht AJR. What are cyclooxygenases and lipoxygenases doing in the driver's seat of carcinogenesis?. Int J Cancer 2006, 119:2247-2254. 10.1002/ijc.22153, 16921484.
2. Chow LW, Loo WT, Toi M. Current directions for COX-2 inhibition in breast cancer. Biomed Pharmacother 2005, 59(Suppl 2):S281-S284.
3. Ryan PD, Goss PE. Adjuvant hormonal therapy in peri- and postmenopausal breast cancer. Oncologist 2006, 11:718-731. 10.1634/theoncologist.11-7-718, 16880231.
4. Gierach GL, et al. Nonsteroidal anti-inflammatory drugs and breast cancer risk in the National Institutes of Health-AARP Diet and Health Study. Breast Cancer Res 2008, 10:R38. 10.1186/bcr2089, 2397540, 18447943.
5. Chandrasekharan NV, et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci 2002, 99:13926-13931. 10.1073/pnas.162468699, 129799, 12242329.
6. Garavito RM, Mulichak AM. The structure of mammalian cyclooxygenases. Annu Rev Biophys Biomol Struct 2003, 32:183-206. 10.1146/annurev.biophys.32.110601.141906, 12574066.
7. Kaduce TL, Figard PH, Leifur R, Spector AA. Formation of 9-hydroxyoctadecadienoic acid from linoleic acid in endothelial cells. J Biol Chem 1989, 264:6823-6830.
8. Chan BS, Satriano JA, Pucci M, Schuster VL. Mechanism of prostaglandin E2 transport across the plasma membrane of HeLa cells and Xenopus oocytes expressing the prostaglandin transporter "PGT". J Biol Chem 1998, 273:6689-6697. 10.1074/jbc.273.12.6689, 9506966.
9. Ushikubi F, et al. Impaired febrile response in mice lacking the prostaglandin E receptor subtype EP3. Nature 1998, 395:281-284. 10.1038/26233, 9751056.
10. Sugimoto Y, Segi E, Tsuboi K, Ichikawa A, Narumiya S. Female reproduction in mice lacking the prostaglandin F receptor. Roles of prostaglandin and oxytocin receptors in parturition. Adv Exp Med Biol 1998, 449:317-321. 10.1007/978-1-4615-4871-3_39, 10026819.
11. Murata T, et al. Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature 1997, 388:678-682. 10.1038/41780, 9262402.
12. Lim H, et al. Cyclo-oxygenase-2-derived prostacyclin mediates embryo implantation in the mouse via PPARdelta. Genes Dev 1999, 13:1561-1574. 10.1101/gad.13.12.1561, 316805, 10385625.
13. Coleman RA, Smith WL, Narumiya S. International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol Rev 1994, 46:205-229.
14. Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol Rev 1999, 79:1193-1226.
15. Dubois RN, et al. Cyclooxygenase in biology and disease. FASEB J 1998, 12:1063-1073.
16. Lydford SJ, McKechnie KC, Dougall IG. Pharmacological studies on prostanoid receptors in the rabbit isolated saphenous vein: a comparison with the rabbit isolated ear artery. Br J Pharmacol 1996, 117:13-20. 10.1111/j.1476-5381.1996.tb15148.x, 1909359, 8825337.
17. Funk CD, et al. Cloning and expression of a cDNA for the human prostaglandin E receptor EP1 subtype. J Biol Chem 1993, 268:26767-26772.
18. Sharif NA, Davis TL. Cloned human EP1 prostanoid receptor pharmacology characterized using radioligand binding techniques. J Pharm Pharmacol 2002, 54:539-547. 10.1211/0022357021778655, 11999132.
19. An S, Yang J, Xia M, Goetzl EJ. Cloning and expression of the EP2 subtype of human receptors for prostaglandin E2. Biochem Biophys Res Commun 1993, 197:263-270. 10.1006/bbrc.1993.2470, 8250933.
20. Yang J, Xia M, Goetzl EJ, An S. Cloning and expression of the EP3-subtype of human receptors for prostaglandin E2. Biochem Biophys Res Commun 1994, 198:999-1006. 10.1006/bbrc.1994.1142, 8117308.
21. Bastien L, Sawyer N, Grygorczyk R, Metters KM, Adam M. Cloning, functional expression, and characterization of the human prostaglandin E2 receptor EP2 subtype. J Biol Chem 1994, 269:11873-11877.
22. Batshake B, Nilsson C, Sundelin J. Molecular characterization of the mouse prostanoid EP1 receptor gene. Eur J Biochem 1995, 231:809-814. 10.1111/j.1432-1033.1995.tb20765.x, 7649181.
23. Regan JW, et al. Cloning of a novel human prostaglandin receptor with characteristics of the pharmacologically defined EP2 subtype. Mol Pharmacol 1994, 46:213-220.
24. Hizaki H, et al. Abortive expansion of the cumulus and impaired fertility in mice lacking the prostaglandin E receptor subtype EP(2). Proc Natl Acad Sci USA 1999, 96:10501-10506. 10.1073/pnas.96.18.10501, 17918, 10468638.
25. Sheller JR, Mitchell D, Meyrick B, Oates J, Breyer R. EP(2) receptor mediates bronchodilation by PGE(2) in mice. J Appl Physiol 2000, 88:2214-2218.
26. Boie Y, et al. Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes. Eur J Pharmacol 1997, 340:227-241. 10.1016/S0014-2999(97)01383-6, 9537820.
27. Katsuyama M, et al. The mouse prostaglandin E receptor EP2 subtype: cloning, expression, and northern blot analysis. FEBS Lett 1995, 372:151-156. 10.1016/0014-5793(95)00966-D, 7556658.
28. Kotani M, et al. Structural organization of the human prostaglandin EP3 receptor subtype gene (PTGER3). Genomics 1997, 40:425-434. 10.1006/geno.1996.4585, 9073510.
29. Namba T, et al. Alternative splicing of C-terminal tail of prostaglandin E receptor subtype EP3 determines G-protein specificity. Nature 1993, 365:166-170. 10.1038/365166a0, 8396726.
30. Aoki J, et al. Signal transduction pathway regulating prostaglandin EP3 receptor-induced neurite retraction: requirement for two different tyrosine kinases. Biochem J 1999, 340(Pt 2):365-369. 1220258, 10333476.
31. Audoly LP, et al. Prostaglandin E-prostanoid-3 receptor activation of cyclic AMP response element-mediated gene transcription. J Pharmacol Exp Ther 1999, 289:140-148.
32. Hasegawa H, Negishi M, Ichikawa A. Two isoforms of the prostaglandin E receptor EP3 subtype different in agonist-independent constitutive activity. J Biol Chem 1996, 271:1857-1860. 10.1074/jbc.271.4.1857, 8567630.
33. Audoly LP, et al. Role of EP(2) and EP(3) PGE(2) receptors in control of murine renal hemodynamics. Am J Physiol Heart Circ Physiol 2001, 280:H327-H333.
34. Fabre JE, et al. Activation of the murine EP3 receptor for PGE2 inhibits cAMP production and promotes platelet aggregation. J Clin Invest 2001, 107:603-610. 10.1172/JCI10881, 199422, 11238561.
35. Sugimoto Y, Narumiya S, Ichikawa A. Distribution and function of prostanoid receptors: studies from knockout mice. Prog Lipid Res 2000, 39:289-314. 10.1016/S0163-7827(00)00008-4, 10856600.
36. Kiriyama M, et al. Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol 1997, 122:217-224. 10.1038/sj.bjp.0701367, 1564924, 9313928.
37. Kay AB, Barata L, Meng Q, Durham SR, Ying S. Eosinophils and eosinophil-associated cytokines in allergic inflammation. Int Arch Allergy Immunol 1997, 113:196-199. 10.1159/000237545, 9130521.
38. Hayaishi O. Molecular mechanisms of sleep-wake regulation: a role of prostaglandin D2. Philos Trans R Soc Lond B Biol Sci 2000, 355:275-280. 10.1098/rstb.2000.0564, 1692734, 10724461.
39. Eguchi N, et al. Lack of tactile pain (allodynia) in lipocalin-type prostaglandin D synthase-deficient mice. Proc Natl Acad Sci USA 1999, 96:726-730. 10.1073/pnas.96.2.726, 15204, 9892701.
40. Boie Y, Sawyer N, Slipetz DM, Metters KM, Abramovitz M. Molecular cloning and characterization of the human prostanoid DP receptor. J Biol Chem 1995, 270:18910-18916. 10.1074/jbc.270.32.18910, 7642548.
41. Nagata K, et al. CRTH2, an orphan receptor of T-helper-2-cells, is expressed on basophils and eosinophils and responds to mast cell-derived factor(s). FEBS Lett 1999, 459:195-199. 10.1016/S0014-5793(99)01251-X, 10518017.
42. Norel X, et al. Prostanoid receptors involved in the relaxation of human bronchial preparations. Br J Pharmacol 1999, 126:867-872. 10.1038/sj.bjp.0702392, 1571227, 10193766.
43. Walch L, et al. Prostanoid receptors involved in the relaxation of human pulmonary vessels. Br J Pharmacol 1999, 126:859-866. 10.1038/sj.bjp.0702393, 1571232, 10193765.
44. Hirai H, et al. Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. J Exp Med 2001, 193:255-261. 10.1084/jem.193.2.255, 2193345, 11208866.
45. Monneret G, Gravel S, Diamond M, Rokach J, Powell WS. Prostaglandin D2 is a potent chemoattractant for human eosinophils that acts via a novel DP receptor. Blood 2001, 98:1942-1948. 10.1182/blood.V98.6.1942, 11535533.
46. Horton EW, Poyser NL. Uterine luteolytic hormone: a physiological role for prostaglandin F2alpha. Physiol Rev 1976, 56:595-651.
47. Barnard JW, Ward RA, Taylor AE. Evaluation of prostaglandin F2 alpha and prostacyclin interactions in the isolated perfused rat lung. J Appl Physiol 1992, 72:2469-2474.
48. Adams JW, et al. Prostaglandin F2 alpha stimulates hypertrophic growth of cultured neonatal rat ventricular myocytes. J Biol Chem 1996, 271:1179-1186. 10.1074/jbc.271.2.1179, 8557648.
49. Abramovitz M, et al. Cloning and expression of a cDNA for the human prostanoid FP receptor. J Biol Chem 1994, 269:2632-2636.
50. Pierce KL, Fujino H, Srinivasan D, Regan JW. Activation of FP prostanoid receptor isoforms leads to Rho-mediated changes in cell morphology and in the cell cytoskeleton. J Biol Chem 1999, 274:35944-35949. 10.1074/jbc.274.50.35944, 10585482.
51. Muller K, Krieg P, Marks F, Furstenberger G. Expression of PGF(2alpha) receptor mRNA in normal, hyperplastic and neoplastic skin. Carcinogenesis 2000, 21:1063-1066. 10.1093/carcin/21.5.1063, 10783334.
52. Nakajima T, et al. New Fluoroprostaglandin F(2alpha) Derivatives with Prostanoid FP-Receptor Agonistic Activity as Potent Ocular-Hypotensive Agents. Biol Pharm Bull 2003, 26:1691-1695. 10.1248/bpb.26.1691, 14646172.
53. Bunting S, Gryglewski R, Moncada S, Vane JR. Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and coeliac ateries and inhibits platelet aggregation. Prostaglandins 1976, 12:897-913.
54. Moncada S. Eighth Gaddum Memorial Lecture. University of London Institute of Education, December 1980. Biological importance of prostacyclin. Br J Pharmacol 1982, 76:3-31. 10.1111/j.1476-5381.1982.tb09186.x, 2068748, 7044460.
55. Moncada S, Higgs EA, Vane JR. Human arterial and venous tissues generate prostacyclin (prostaglandin x), a potent inhibitor of platelet aggregation. Lancet 1977, 1:18-20.
56. Vane JR, Botting RM. Pharmacodynamic profile of prostacyclin. Am J Cardiol 1995, 75:3A-10A. 10.1016/S0002-9149(99)80377-4, 7840052.
57. Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 2000, 69:145-182. 10.1146/annurev.biochem.69.1.145, 10966456.
58. McAdam BF, et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA 1999, 96:272-277. 10.1073/pnas.96.1.272, 15129, 9874808.
59. Catella-Lawson F, et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther 1999, 289:735-741.
60. Brock TG, McNish RW, Peters-Golden M. Arachidonic acid is preferentially metabolized by cyclooxygenase-2 to prostacyclin and prostaglandin E2. J Biol Chem 1999, 274:11660-11666. 10.1074/jbc.274.17.11660, 10206978.
61. Armstrong RA, Lawrence RA, Jones RL, Wilson NH, Collier A. Functional and ligand binding studies suggest heterogeneity of platelet prostacyclin receptors. Br J Pharmacol 1989, 97:657-668. 10.1111/j.1476-5381.1989.tb12001.x, 1854572, 2474350.
62. Namba T, et al. cDNA cloning of a mouse prostacyclin receptor. Multiple signaling pathways and expression in thymic medulla. J Biol Chem 1994, 269:9986-9992.
63. Breyer RM, Bagdassarian CK, Myers SA, Breyer MD. Prostanoid receptors: subtypes and signaling. Annu Rev Pharmacol Toxicol 2001, 41:661-690. 10.1146/annurev.pharmtox.41.1.661, 11264472.
64. Smyth EM, Austin SC, Reilly MP, FitzGerald GA. Internalization and sequestration of the human prostacyclin receptor. J Biol Chem 2000, 275:32037-32045.
65. Dorn GW, Sens D, Chaikhouni A, Mais D, Halushka PV. Cultured human vascular smooth muscle cells with functional thromboxane A2 receptors: measurement of U46619-induced 45calcium efflux. Circ Res 1987, 60:952-956. 10.1161/01.RES.60.6.952, 2954721.
66. Pakala R, Willerson JT, Benedict CR. Effect of serotonin, thromboxane A2, and specific receptor antagonists on vascular smooth muscle cell proliferation. Circulation 1997, 96:2280-2286. 10.1161/01.CIR.96.7.2280, 9337201.
67. FitzGerald GA. Mechanisms of platelet activation: thromboxane A2 as an amplifying signal for other agonists. Am J Cardiol 1991, 68:11B-15B. 10.1016/0002-9149(91)90379-Y, 1892057.
68. Ali S, Davis MG, Becker MW, Dorn GW. Thromboxane A2 stimulates vascular smooth muscle hypertrophy by up-regulating the synthesis and release of endogenous basic fibroblast growth factor. J Biol Chem 1993, 268:17397-17403.
69. Hirata M, et al. Cloning and expression of cDNA for a human thromboxane A2 receptor. Nature 1991, 349:617-620. 10.1038/349617a0, 1825698.
70. Raychowdhury MK, et al. Alternative splicing produces a divergent cytoplasmic tail in the human endothelial thromboxane A2 receptor. J Biol Chem 1995, 270:7011. 10.1074/jbc.270.12.7011, 7896853.
71. Miggin SM, Kinsella BT. Expression and tissue distribution of the mRNAs encoding the human thromboxane A2 receptor (TP) alpha and beta isoforms. Biochim Biophys Acta 1998, 1425:543-559. 10.1016/S0304-4165(98)00109-3, 9838218.
72. Needleman P, Wyche A, Raz A. Platelet and blood vessel arachidonate metabolism and interactions. J Clin Invest 1979, 63:345-349. 10.1172/JCI109309, 371959, 372240.
73. Cogolludo A, Moreno L, Bosca L, Tamargo J, Perez-Vizcaino F. Thromboxane A2-induced inhibition of voltage-gated K+ channels and pulmonary vasoconstriction: role of protein kinase Czeta. Circ Res 2003, 93:656-663. 10.1161/01.RES.0000095245.97945.FE, 12970114.
74. Sullivan P, Smyth EM. Herterodimerization of the a and b isoforms of the human thromboxane receptor. Arterioscler Thromb Vasc Biol 2002, 22:878.
75. Powles TJ, Dowsett M, Easty GC, Easty DM, Neville AM. Breast-cancer osteolysis, bone metastases, and anti-osteolytic effect of aspirin. Lancet 1976, 307:608-610.
76. Sung S, et al. Overexpression of cyclooxygenase-2 in NCI-H292 human alveolar epithelial carcinoma cells: Roles of p38 MAPK, ERK-1/2, and PI3K/PKB signaling proteins. J Cell Biochem 2011, 112:3015-3024. 10.1002/jcb.23226, 21678473.
77. Kim BH, et al. Cyclooxygenase-2 overexpression in chronic inflammation associated with benign prostatic hyperplasia: is it related to apoptosis and angiogenesis of prostate cancer?. Korean J Urol 2011, 52:253-259. 10.4111/kju.2011.52.4.253, 3085617, 21556211.
78. Kulkarni S, et al. Cyclooxygenase-2 Is Overexpressed in Human Cervical Cancer. Clin Cancer Res 2001, 7:429-434.
79. Wang M, He Y, Shi L, Shi C. Multivariate analysis by Cox proportional hazard model on prognosis of patient with epithelial ovarian cancer. Eur J Gynaecol Oncol 2011, XXXII:7.
80. Nie D. Cyclooxygenases and lipoxygenases in prostate and breast cancers. Front Biosci 2007, 12:1574-1585. 10.2741/2170, 17127404.
81. Park S-W, et al. he influence of cyclooxygenase-1 expression on the efficacy of cyclooxygenase-2 inhibition in head and neck squamous cell carcinoma cell lines. Anti-Cancer Drugs 22:416-423.
82. Langenbach R, Loftin CD, Lee C, Tiano H. Cyclooxygenase-deficient Mice: A Summary of Their Characteristics and Susceptibilities to Inflammation and Carcinogenesis. Ann N Y Acad Sci 1999, 889:52-61. 10.1111/j.1749-6632.1999.tb08723.x, 10668482.
83. Tiano HF, et al. Deficiency of Either Cyclooxygenase (COX)-1 or COX-2 Alters Epidermal Differentiation and Reduces Mouse Skin Tumorigenesis. Cancer Res 2002, 62:3395-3401.
84. Rundhaug JE, Mikulec C, Pavone A, Fischer SM. A role for cyclooxygenase-2 in ultraviolet light-induced skin carcinogenesis. Mol Carcinog 2007, 46:692-698. 10.1002/mc.20329, 17443745.
85. Müller-Decker K, et al. Transgenic cyclooxygenase-2 overexpression sensitizes mouse skin for carcinogenesis. Proc Natl Acad Sci 2002, 99:12483-12488. 10.1073/pnas.192323799, 129471, 12221288.
86. Liu H, et al. COX-2 expression is correlated with VEGF-C, lymphangiogenesis and lymph node metastasis in human cervical cancer. Microvasc Res 2011, 82:131-140. 10.1016/j.mvr.2011.04.011, 21600223.
87. Williams CS, Tsujii M, Reese J, Dey SK, DuBois RN. Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest 2000, 105:1589-1594. 10.1172/JCI9621, 300858, 10841517.
88. Sales KJ, Boddy SC, Williams AR, Anderson RA, Jabbour HN. F-prostanoid receptor regulation of fibroblast growth factor 2 signaling in endometrial adenocarcinoma cells. Endocrinology 2007, 148:3635-3644. 10.1210/en.2006-1517, 17478553.
89. Chu J, Lloyd FL, Trifan OC, Knapp B, Rizzo MT. Potential Involvement of the Cyclooxygenase-2 Pathway in the Regulation of Tumor-associated Angiogenesis and Growth in Pancreatic Cancer1. Mol Cancer Ther 2003, 2:1-7. 10.1186/1476-4598-2-1, 12533667.
90. Chuang HC, Kardosh A, Gaffney KJ, Petasis NA, Schonthal AH. COX-2 inhibition is neither necessary nor sufficient for celecoxib to suppress tumor cell proliferation and focus formation in vitro. Mol Cancer 2008, 7:38. 2396175, 18485224.
91. Tegeder I, Pfeilschifter J, Geisslinger G. Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J 2001, 15:2057-2072. 10.1096/fj.01-0390rev, 11641233.
92. Khromova N, Kopnin P, Rybko V, Kopnin BP. Downregulation of VEGF-C expression in lung and colon cancer cells decelerates tumor growth and inhibits metastasis via multiple mechanisms. Oncogene 2012, 31:1389-1397. 10.1038/onc.2011.330, 21804602.
93. Schwarz-Cruz-y-Celis A, M-ZJ Cancer stem cells. Rev 2011, 63:179-186. M-ZJ.
94. Halamka M, et al. Plasma levels of vascular endothelial growth factor during and after radiotherapy in combination with celecoxib in patients with advanced head and neck cancer. Oral Oncol 2011, 47:763-767. 10.1016/j.oraloncology.2011.05.009, 21696999.
95. Yao M, et al. Inhibition of Cyclooxygenase-2 by Rofecoxib Attenuates the Growth and Metastatic Potential of Colorectal Carcinoma in Mice. Cancer Res 2003, 63:586-592.
96. Wang MT, Honn KV, Nie D. Cyclooxygenases, prostanoids, and tumor progression. Cancer Metastasis Rev 2007, 26:525-534. 10.1007/s10555-007-9096-5, 17763971.
97. Muller-Decker K, Furstenberger G. The cyclooxygenase-2-mediated prostaglandin signaling is causally related to epithelial carcinogenesis. Mol Carcinog 2007, 46:705-710. 10.1002/mc.20326, 17546626.
98. Nakanishi M, Gokhale V, Meuillet EJ, Rosenberg DW. mPGES-1 as a target for cancer suppression: A comprehensive invited review "Phospholipase A2 and lipid mediators". Biochimie 2010, 92:660-664. 10.1016/j.biochi.2010.02.006, 2898715, 20159031.
99. Menter DG, Schilsky RL, DuBois RN. Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward. Clin Cancer Res 2010, 16:1384-1390. 10.1158/1078-0432.CCR-09-0788, 20179228.
100. Radmark O, Samuelsson B. Microsomal prostaglandin E synthase-1 and 5-lipoxygenase: potential drug targets in cancer. J Intern Med 2010, 268:5-14.
101. Nie D, et al. Differential expression of thromboxane synthase in prostate carcinoma: role in tumor cell motility. Am J Pathol 2004, 164:429-439. 10.1016/S0002-9440(10)63133-1, 1602253, 14742249.
102. Osawa T, et al. Prostacyclin receptor in tumor endothelial cells promotes angiogenesis in an autocrine manner. Cancer Sci 2012, 103:1038-1044. 10.1111/j.1349-7006.2012.02261.x, 22380928.
103. Wu J, et al. Prostaglandin E2 regulates renal cell carcinoma invasion through the EP4 receptor-Rap GTPase signal transduction pathway. J Biol Chem 2011, 286:33954-33962. 10.1074/jbc.M110.187344, 3190815, 21832044.
104. Timoshenko AV, Xu G, Chakrabarti S, Lala PK, Chakraborty C. Role of prostaglandin E2 receptors in migration of murine and human breast cancer cells. Exp Cell Res 2003, 289:265-274. 10.1016/S0014-4827(03)00269-6, 14499627.
105. Yang SF, et al. Prostaglandin E2/EP1 signaling pathway enhances intercellular adhesion molecule 1 (ICAM-1) expression and cell motility in oral cancer cells. J Biol Chem 2010, 285:29808-29816. 10.1074/jbc.M110.108183, 2943269, 20647315.
106. Ma X, et al. Prostaglandin E receptor EP1 suppresses breast cancer metastasis and is linked to survival differences and cancer disparities. Mol Cancer Res 2010, 8:1310-1318. 10.1158/1541-7786.MCR-10-0003, 2974016, 20858737.
107. Hu S, et al. Involvement of the prostaglandin E receptor EP2 in paeoniflorin-induced human hepatoma cell apoptosis. Anticancer Drugs 2013, 24:140-149. 10.1097/CAD.0b013e32835a4dac, 23069790.
108. Holt D, Ma X, Kundu N, Fulton A. Prostaglandin E(2) (PGE (2)) suppresses natural killer cell function primarily through the PGE(2) receptor EP4. Cancer Immunol Immunother 2011, 60:1577-1586. 10.1007/s00262-011-1064-9, 21681369.
109. Chen Y, Perussia B, Campbell KS. Prostaglandin D2 suppresses human NK cell function via signaling through D prostanoid receptor. J Immunol 2007, 179:2766-2773.
110. Murata T, et al. Role of prostaglandin D2 receptor DP as a suppressor of tumor hyperpermeability and angiogenesis in vivo. Proc Natl Acad Sci USA 2008, 105:20009-20014. 10.1073/pnas.0805171105, 2596745, 19060214.
111. Wang S, Yang Q, Fung KM, Lin HK. AKR1C2 and AKR1C3 mediated prostaglandin D2 metabolism augments the PI3K/Akt proliferative signaling pathway in human prostate cancer cells. Mol Cell Endocrinol 2008, 289:60-66. 10.1016/j.mce.2008.04.004, 18508192.
112. Keightley MC, Sales KJ, Jabbour HN. PGF2alpha-F-prostanoid receptor signalling via ADAMTS1 modulates epithelial cell invasion and endothelial cell function in endometrial cancer. BMC Cancer 2010, 10:488. 10.1186/1471-2407-10-488, 2944181, 20840749.
113. Sales KJ, et al. A novel angiogenic role for prostaglandin F2alpha-FP receptor interaction in human endometrial adenocarcinomas. Cancer Res 2005, 65:7707-7716. 2694301, 16140938.
114. Schirner M, Kraus C, Lichtner RB, Schneider MR, Hildebrand M. Tumor metastasis inhibition with the prostacyclin analogue cicaprost depends on discontinuous plasma peak levels. Prostaglandins Leukot Essent Fatty Acids 1998, 58:311-317. 10.1016/S0952-3278(98)90041-2, 9654405.
115. Li X, Tai HH. Activation of thromboxane A(2) receptors induces orphan nuclear receptor Nurr1 expression and stimulates cell proliferation in human lung cancer cells. Carcinogenesis 2009, 30:1606-1613. 10.1093/carcin/bgp161, 19570744.
116. Turner EC, et al. Identification of an interaction between the TPalpha and TPbeta isoforms of the human thromboxane A2 receptor with protein kinase C-related kinase (PRK) 1: implications for prostate cancer. J Biol Chem 2011, 286:15440-15457. 10.1074/jbc.M110.181180, 3083147, 21357687.
117. Moussa O, et al. Novel role of thromboxane receptors beta isoform in bladder cancer pathogenesis. Cancer Res 2008, 68:4097-4104. 10.1158/0008-5472.CAN-07-6560, 18519668.
118. Nie D, et al. Thromboxane A2 receptors in prostate carcinoma: expression and its role in regulating cell motility via small GTPase Rho. Cancer Res 2008, 68:115-121. 10.1158/0008-5472.CAN-07-1018, 18172303.
119. Liu X-H, Yao S, Kirschenbaum A, Levine AC. NS398, a Selective Cyclooxygenase-2 Inhibitor, Induces Apoptosis and Down-Regulates bcl-2 Expression in LNCaP Cells. Cancer Res 1998, 58:4245-4249.
120. Xue W-P, et al. Phase I clinical trial of nasopharyngeal radiotherapy and concurrent celecoxib for patients with locoregionally advanced nasopharyngeal carcinoma. Oral Oncol 2011, 47:753-757. 10.1016/j.oraloncology.2011.06.002, 21708478.
121. Seiz M, et al. Far-distant metastases along the CSF pathway of glioblastoma multiforme during continuous low-dose chemotherapy with temozolomide and celecoxib. Neurosurg Rev 2010, 33:375-381. 10.1007/s10143-010-0253-x, 20306105.
122. Mao JT, et al. Lung cancer chemoprevention with celecoxib in former smokers. Cancer Prevention Res 2011, 4:984-993.
123. Koch A, et al. Effect of celecoxib on survival in patients with advanced non-small cell lung cancer: A double blind randomised clinical phase III trial (CYCLUS study) by the Swedish Lung Cancer Study Group. Eur J Cancer 2011, 47:1546-1555. 10.1016/j.ejca.2011.03.035, 21565487.
124. Vinogradova Y, Coupland C, Hippisley-Cox J. Exposure to cyclooxygenase-2 inhibitors and risk of cancer: nested case-control studies. Br J Cancer 2011, 105:452-459. 10.1038/bjc.2011.252, 3172909, 21750557.
125. Wang J, et al. Prostacyclin administration as a beneficial supplement to the conventional cancer chemotherapy. Med Hypotheses 2011, 76:695-696. 10.1016/j.mehy.2011.01.036, 21345596.
126. Cuneo KC, Fu A, Osusky KL, Geng L. Effects of vascular endothelial growth factor receptor inhibitor SU5416 and prostacyclin on murine lung metastasis. Anticancer Drugs 2007, 18:349-355. 10.1097/CAD.0b013e328011fdab, 17264769.
127. Griffoni C, et al. Selective inhibition of prostacyclin synthase activity by rofecoxib. J Cell Mol Med 2007, 11:327-338. 10.1111/j.1582-4934.2007.00021.x, 17488481.
128. Nakae K, et al. A prostacyclin receptor antagonist inhibits the sensitized release of substance P from rat sensory neurons. J Pharmacol Exp Ther 2005, 315:1136-1142. 10.1124/jpet.105.091967, 16109742.
129. Kaneshiro T, et al. Inhibition of prostaglandin E(2) signaling through the EP(1) receptor does not affect prostacyclin production in human endothelial cells. Prostaglandins Other Lipid Mediat 2009, 90:31-36. 10.1016/j.prostaglandins.2009.07.003, 2767438, 19647091.
130. Ikawa Y, Fujino H, Otake S, Murayama T. Indomethacin antagonizes EP(2) prostanoid receptor activation in LS174T human colon cancer cells. Eur J Pharmacol 2012, 680:16-21. 10.1016/j.ejphar.2012.01.033, 22329897.
131. Koeberle A, et al. Green tea epigallocatechin-3-gallate inhibits microsomal prostaglandin E(2) synthase-1. Biochem Biophys Res Commun 2009, 388:350-354. 10.1016/j.bbrc.2009.08.005, 19665000.
132. Hardtner C, Multhoff G, Falk W, Radons J. (-)-Epigallocatechin-3-gallate, a green tea-derived catechin, synergizes with celecoxib to inhibit IL-1-induced tumorigenic mediators by human pancreatic adenocarcinoma cells Colo357. Eur J Pharmacol 2012, 684:36-43. 10.1016/j.ejphar.2012.03.039, 22497997.
133. Watts IS, Wharton KA, White BP, Lumley P. Thromboxane (Tx) A2 receptor blockade and TxA2 synthase inhibition alone and in combination: comparison of anti-aggregatory efficacy in human platelets. Br J Pharmacol 1991, 102:497-505. 10.1111/j.1476-5381.1991.tb12200.x, 1918008, 1826620.
134. Chouinard ML, et al. Pharmacokinetics and biochemical efficacy of pirmagrel, a thromboxane synthase inhibitor, in renal allograft recipients. Clin Pharmacol Ther 1992, 52:597-604. 10.1038/clpt.1992.197, 1458769.
135. Vermylen J, et al. Thromboxane synthetase inhibition as antithrombotic strategy. Lancet 1981, 1:1073-1075.
136. Suehiro T, et al. Thromboxane A2 in preservation-reperfusion injury: the effect of thromboxane A2 synthetase inhibitor. J Surg Res 1996, 62:216-223. 10.1006/jsre.1996.0198, 8632642.
137. Oketani K, Inoue T, Murakami M. Effect of E3040, an inhibitor of 5-lipoxygenase and thromboxane synthase, on rat bowel damage induced by lipopolysaccharide. Eur J Pharmacol 2001, 427:159-166. 10.1016/S0014-2999(01)01234-1, 11557269.
138. Shi H, et al. Effect of thromboxane A2 inhibitors on allergic pulmonary inflammation in mice. Eur Respir J 1998, 11:624-629.
139. Francis HP, Greenham SJ, Patel UP, Thompson AM, Gardiner PJ. BAY u3405 an antagonist of thromboxane A2- and prostaglandin D2-induced bronchoconstriction in the guinea-pig. Br J Pharmacol 1991, 104:596-602. 10.1111/j.1476-5381.1991.tb12475.x, 1908239, 1797323.
140. Navarro-Nunez L, et al. Apigenin inhibits platelet adhesion and thrombus formation and synergizes with aspirin in the suppression of the arachidonic acid pathway. J Agric Food Chem 2008, 56:2970-2976. 10.1021/jf0723209, 18410117.
141. Guerrero JA, et al. Flavonoids inhibit the platelet TxA(2) signalling pathway and antagonize TxA(2) receptors (TP) in platelets and smooth muscle cells. Br J Clin Pharmacol 2007, 64:133-144. 10.1111/j.1365-2125.2007.02881.x, 2000638, 17425630.
142. Nakahata N. Thromboxane A2: physiology/pathophysiology, cellular signal transduction and pharmacology. Pharmacol Ther 2008, 118:18-35. 10.1016/j.pharmthera.2008.01.001, 18374420.
143. Sung YM, He G, Fischer SM. Lack of Expression of the EP2 but not EP3 Receptor for Prostaglandin E2 Results in Suppression of Skin Tumor Development. Cancer Res 2005, 65:9304-9311. 10.1158/0008-5472.CAN-05-1015, 16230392.
144. Shoji Y, et al. Prostaglandin E receptor EP3 deficiency modifies tumor outcome in mouse two-stage skin carcinogenesis. Carcinogenesis 2005, 26:2116-2122. 10.1093/carcin/bgi193, 16051640.
145. Majima M, Amano H, Hayashi I. Prostanoid receptor signaling relevant to tumor growth and angiogenesis. Trends Pharmacol Sci 2003, 24:524-529. 10.1016/j.tips.2003.08.005, 14559404.
146. Sales KJ, Milne SA, Williams ARW, Anderson RA, Jabbour HN. Expression, localization, and signaling of prostaglandin F2α receptor in human endometrial adenocarcinoma: regulation of proliferation by activation of the epidermal growth factor receptor and mitogen-activated protein kinase signaling pathways. J Clin Endocrinol Metabol 2004, 89:986-993.
147. Clària J, Serhan CN. Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. Proc Natl Acad Sci 1995, 92:9475-9479. 10.1073/pnas.92.21.9475, 40824, 7568157.
148. Xu XC, Liang Z, Song S, Menter D, Subbarayan V, Iyengar S, Tang DG, Lippman SM, SS Reduced 15S-lipoxygenase-2 expression in esophageal cancer specimens and cells and upregulation in vitro by the cyclooxygenase-2 inhibitor, NS398. Neoplasia 2003, 5:121-127. 1502398, 12659684, SS.
149. Mao JT, et al. Modulation of pulmonary leukotriene B4 production by cyclooxygenase-2 inhibitors and lipopolysaccharide. Clin Cancer Res 2004, 10:6872-6878. 10.1158/1078-0432.CCR-04-0945, 15501964.
150. Gao Y, Yokota R, Tang S, Ashton AW, Ware JA. Reversal of angiogenesis in vitro, induction of apoptosis, and inhibition of AKT phosphorylation in endothelial cells by thromboxane A(2). Circ Res 2000, 87:739-745. 10.1161/01.RES.87.9.739, 11055976.
151. Williams CD, et al. A high ratio of dietary n-6/n-3 polyunsaturated fatty acids is associated with increased risk of prostate cancer. Nutr Res 2011, 31:1-8.
152. Sapieha P, et al. 5-Lipoxygenase Metabolite 4-HDHA Is a Mediator of the Antiangiogenic Effect of ω-3 Polyunsaturated Fatty Acids. Sci Transl Med 2011, 3:69ra12. 10.1126/scitranslmed.3001571, 21307302.